^
Association details:
| Biomarker: | PIK3CA mutation + HR positive |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) + lapatinib (EGFR inhibitor, HER2 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Association of PIK3CA Mutation With Pathologic Complete Response and Outcome by Hormone Receptor Status and Intrinsic Subtype in Early-Stage ERBB2/HER2-Positive Breast Cancer
Published date:
12/20/2023
Excerpt:
When limited to patients treated with paclitaxel plus trastuzumab-based therapy (only trastuzumab or trastuzumab plus lapatinib)...At a median follow-up of 9 years, PIK3CA mutations were significantly associated with worse EFS in the overall cohort (hazard ratio, 2.58 [95% CI, 1.24-5.35]; P = .01), which persisted in a multivariable model including pCR, HR status, stage, and IMS (hazard ratio, 2.52 [95% CI, 1.16-5.47]; P = .02)....In this cohort study of CALGB 40601, PIK3CA mutations were significantly associated with lower pCR rates among patients receiving trastuzumab-based therapy. PIK3CA mutations were also associated with worse EFS in univariable and multivariable Cox proportional hazards regression models, which appeared to be associated with HR-positive and luminal ERBB2/HER2-positive BC.
Secondary therapy:
paclitaxel
DOI:
10.1001/jamanetworkopen.2023.48814
